What question did this study set out to answer?

The study aims to evaluate the structural characteristics of valsartan regarding impurity formation and quantify a specific impurity.

Valsartan—Mutagenic Nitroso Drug Substance Related Impurity, Structural Evaluation, Carcinogenic Potency Categorization Assessment; a Novel and Extremely Sensitive Quantification Method for Impurity in Drug Substances Using LC‐MS/MS

View Full Paper

Ask AI

Bookmark

Authors

Evaluation assesses carcinogenic potency and impurity levels in valsartan, suggesting new safety measures.

The study aims to evaluate the structural characteristics of valsartan regarding impurity formation and quantify a specific impurity.
Conducted structural analysis of valsartan under acidic conditions.
Developed and validated an LC-MS/MS method for quantifying N-Nitroso Desvaleryl Valsartan.
Applied gradient elution with formic acid and acetonitrile on a Zorbax SB-C18 column.
Identified N-Nitroso Desvaleryl Valsartan as a significant impurity.
Classified the impurity in carcinogenicity Category 5 with a daily intake limit of 1500 ng/day.
Validated the method to detect levels as low as 96 ng/day with high linearity and precision.

Vakkala et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark